0OP.F Stock Analysis
0O
Uncovered
OptiNose Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
OptiNose, Inc. operates as a pharmaceutical company. The company is headquartered in Yardley, Pennsylvania and currently employs 141 full-time employees. The company went IPO on 2017-10-13. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram, is a therapeutic utilizing its exhalation Delivery System (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. Its powder EDS, which is the EDS used in its ONZETRA Xsail consists of a reusable device body incorporating a flexible mouthpiece to adjust to individual anatomic variations, and a white button piercing assembly to pierce the medication capsule.